AD-101(Addpharma)
- Generic Name
- AD-101(Addpharma)
Alzheimer's Disease Pipeline Shows Promise with 120+ Therapies in Development
• Over 120 Alzheimer's Disease treatment therapies are under development by 110+ companies globally, ranging from preclinical to marketed phases.
• Emerging therapies like NRDN-201, ST-501, and KarXT are in various clinical trial phases, showing potential for significant market impact.
• MapLight Therapeutics initiated a Phase 1 trial for ML-007/PAC, targeting schizophrenia and Alzheimer's disease psychosis, with Phase 2 trials planned.
• The FDA granted conventional approval to Leqembi (lecanemab-irmb), marking the first amyloid beta-directed antibody to transition from accelerated approval.
Sapience Therapeutics' ST316 Receives FDA Clearance for Phase 1-2 Solid Tumor Trial
• Sapience Therapeutics received FDA clearance for its IND application to begin a Phase 1-2 clinical trial of ST316 in patients with solid tumors.
• ST316 is a first-in-class β-catenin antagonist peptide, targeting the Wnt signaling pathway, which is implicated in over 50% of solid tumors.
• The Phase 1 portion will be a dose-escalation study, while Phase 2 will focus on cholangiocarcinoma, colorectal, triple-negative breast, and ovarian cancers.
• Patient dosing is expected to commence in the first half of 2023, evaluating safety, clinical activity, pharmacokinetics, and pharmacodynamics of ST316.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath